RussianPatents.com

Canine influenza virus, compositions containing said virus and application thereof. RU patent 2410427.

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to biotechnology and specifically to isolated canine influenza virus subtype H3N8 which contains HA protein. Described also is a composition which contains an attenuated or inactivated virus and isolated or purified proteins HA, NM, NP, M1, NS1, PA, PB1 and pB2 and fragments thereof.

EFFECT: invention can be used in veterinary, particularly for providing an influenza virus which infects dogs.

17 cl, 16 dwg, 1 ex

IPC classes for russian patent Canine influenza virus, compositions containing said virus and application thereof. RU patent 2410427. (RU 2410427):

C12N7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (medicinal preparations containing viruses A61K0035760000; preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K0039000000)

C07K14/11 - Orthomyxoviridae, e.g. influenza virus

A61K39/145 -

Another patents in same IPC classes:

Viral vaccine against marek's disease / 2410117
Viral vaccine contains cell-associated turkey herpes virus (THV) of "Vladimir" strain, cattle blood serum (CBS) and dimethylsulfoxide (DMSO) in ratio, wt %: 60.0÷80.0; 15.0÷25.0 and 5.0÷15.0 respectively. Strain is deposited in FGI VGNKI collection of microorganisms under registration number (reference) "Vladimir No 124-DEP" THV (further "Strain"). Strain is reproduced in culture of SPF-chicken embryo fibroblast cells (CFE) and reaches titre 3.5·106 PFU/cm3, for vaccine manufacturing used is suspension of infected CFE cells with titre not lower than 5.5·105 PFU/cm3.

Virus-like particles including hybrid protein of ap205 bacteriophage coat protein and antigen polypeptide / 2409667
Modified virus-like particle (VLP) includes hybrid protein which consists of AP205 bacteriophage protein and any antigen. Also, a composition including VLP, being a derivative of RNA-containing AP205 bacteriophage is described. Besides, the invention describes a method for producing said VLP. Modified VLP of the present invention is applicable for producing compositions for inducing immune response for prevention or treatment of diseases, disorders, including infectious diseases, allergies, cancer and drug addiction.

Rnai-modulation of rsv, piv and other respiratory viruses and application thereof / 2409666
Method of decreasing the levels of protein, mRNA or titre of respiratory syncytial virus (RSV) in an airway cell provides the introduction of a siRNA agent. The siRNA agent contains a sense chain 15-23 nucleotides long and a complementary anti-sense chain 15-23 nucleotides long. The siRNA agent is introduced by inhalation or intranasal spraying. There is also presented a method of decreasing the levels of titre of respiratory syncytial virus (RSV) and parainfluenza virus (PIV). Also, the method provides combined introduction of two siRNA agent.

Vaccine preparation / 2409386
Invention refers to biotechnology, particularly concerns a vaccine preparation which can be used for controlling viral and other diseases of infectious nature. A reaction product of cationic oligomer and antigen determinant in an equimolar amount are used as an antigen polypeptide.

General health-improving agent in treating new growths / 2409376
Invention refers to medicine, and concerns a general health-improving agent in treating new growths. Substance of the invention covers avirulent bacteria suspension in a stable, irreversible L-form of strain No. 118-L3 with metabolic products in 1-2 % sodium chloride.

Recombinant plasmid pfastbac-b17r dna containing cowpox virus genome fragment coding alpha/beta-interferon binding protein and bvb17rg baculovirus strain producing soluble alpha/beta-interferon binding protein of cowpox virus / 2405824
Recombinant plasmid pFastBac-B17R DNA carries a cowpox virus genome fragment. BvB 17RG recombinant baculovirus strain is produced with the use of recombinant plasmid pFastBac-B 17R DNA and deposited in the Microorganism Cultures Collection of the Federal State Research Institution 'State Research Centre for Virology and Biotechnology 'Vector' of Federal Service for Supervision of Consumer Rights Protection and Human Welfare' (FGUN GNC VB 'Vector' of Rospotrebnadzor) under No. V-388, characterised as a producer of a soluble analogue protein of cowpox interferons type 1 cell receptor.

Synthetic oligonucleotide primers and method of bovine respiratory syncytial infection rna virus detection by synthetic oligonucleotide primers in polymerase chain reaction (pcr) / 2405039
Bovine respiratory syncytial infection RNA virus is detected with the use of synthetic oligonucleotide primers complementary to a high-conserved genome region of bovine respiratory syncytial infection virus of glycoprotein F gene in polymerase chain reaction. The offered method involves DNA recovery, reverse transcription, amplification of complementary virus DNA (cDNA) on synthetic oligonucleotide primers, transport of an amplification product on gel and reaction assay. PCR is one-rounded. In positive reaction, a fragment corresponding to 381 n.s. is synthesised.

Hepatitis type a virus strain for producing vaccines and diagnostic preparations / 2405037
Strain can be used for prevention and diagnostic purposes in medicine. Strain No. VBA-07 is created for producing vaccines and diagnostic preparations. Strain No. VBA-07 surpasses a prototype strain both in efficiency (the amount of infective virus and virus-specific antigen), and in kinetics of HAV antigen accumulation, and in cultivation time. The strain is deposited in the Microorganism Cultures Collections of JSC 'Vector-BiAlgam' and is registered under No.VB-17.

Method of obtaining virion antigen of tick-borne encephalitis virus / 2402606
Invention relates to field of biotechnology, to method of obtaining virion antigen of tick-borne encephalitis (TBE) virus from antigen-containing material, which includes, mainly, antigen particulars of TBE virus smaller then full-size TBE virions. Claimed method includes centrifuging of antigen-containing material, which includes, mainly, antigen particles of TBE virus smaller than full-size TBE virions with angular acceleration not less than 15000 g.

Method of determining degree of coxsackie b virus strain pathogenicity / 2401864
Degree of pathogenicity of enterovirus strains of Coxsackie B virus is determined basing on research of neuropathogenicity of Coxsackie B virus field strain in conditions of one nest of linear mice. Mice are divided on two groups. One is subjected to artificial infection with field strain. Expressed signs of central nervous system affection in mice infected in natural way are fixed. They are compared with characteristic of control strains of Coxsackie B virus prototype and epidemic ones. In case if character of expressed signs of nervous system affection coincides, correspondence of degree of pathogenicity of field strain to interepidemic one is stated.

Effective influenza vlps / 2369405
Immunogenic vaccine composition comprises macromolecular protein structure containing proteins of bird influenza virus HA, NA, and Ml and a carrier or dilution agent. The suggested group of inventions provides safety recombinant vaccine practice and highly immunogenic self-organised macromolecules integrated in plasmamembranes comprising multivariate replicas of structural protein of bird influenza virus demonstrating neutralising epitopes in native conformations.

Method of influenza vaccination of birds / 2408370
Invention refers to veterinary science. The method implies that the introduced vaccine is mixed with Myramistin. Myramistin is introduced intranasally by 0.2-0.3 ml into each nasal passage of a bird.

Vaccines and methods of treating canine influenza / 2396976
Present invention refers to production of new vaccines and methods of treating the diseases associated with canine influenza virus. The method of immunisation of a dog against influenza virus involves introduction to a specified dog of a therapeutically effective amount of the vaccine containing at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog, and the amount of the specified virus is 10 to 10000 GA units, and the vaccine additionally contains an adjuvant where the adjuvant can be chosen from the metabolised adjuvant, b) the non-metabolised adjuvant, c) 2% alum, d) 5% alum, e) Quil A, and f) cholesterol or any combination thereof. The method for preparing the vaccine against canine influenza virus includes making the composition containing the therapeutically effective amount of at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog. Application of the vaccine prepared by the method for immunisation of dogs against influenza virus.

Method for prevention of bird's flu type a / 2383357
Simultaneously the following operations are carried out: one-time vaccination of bird with inactivated emulsified vaccine against bird's flu from subtype H5N2 and feeding of chemical preparation "Abaktan-R" in dose of 20 mg/kg of body weight once a day during 14 days.

Strain of bird flu virus a/chicken/kurgan/05/2005 subtype h5n1 for studying of activity of medical and preventive preparations against flu virus / 2361917
Strain-producer of the bird flu virus A/Chicken/Kurgan/05/2005 possesses high efficiency. The strain is deposited in the Collection of microorganisms of the State centre of science of virology and biotechnology "Vector" at registration number V-349. On the basis of the strain the adequate model for studying of activity of antiviral preparations and efficiency of vaccines against the bird flu virus (subtype H5N1) in vivo is created.

Sphingoid polyalkylamine conjugates for bacterination / 2361577
Invention concerns area of medicine and concerns application of the sphyngoid-polyalkylamine conjugate - N-palmitoile-D-erythrosphyngosilecarbamoilspermine (CCS) as a keeping agent for biologically active molecules, such as antigens. The invention also concerns the way of modulation of the immune response at the subject. In the specific version of realisation of the invention the pharmaceutical composition represents a vaccine against flu, including CCS and antigens of a virus of flu - hemagglutinin and a neuraminidase. Advantage of the invention consists in intensifying of the immune response.

Universal avian influenza virus vaccine / 2358981
There are offered recombinant protein molecule M2E-HBC, and virus-like particles formed of such molecules. The recombinant virus-like particle based on nuclear antigen of hepatitis B virus represents surface polypeptides of outer domain M2 of avian influenza virus protein. The produced virus-like particles are characterised with high immunogenicity. There is also disclosed vaccine for the infection caused by avian influenza virus, including such virus-like particles as an active agent.

Isolated recombinant influenza virus and methods of production / 2351651
Invention refers to molecular biology, virology and genetic engineering. There are disclosed method of producing recombinant influenza virus with mutant gene NB of membrane protein, recombinant influenza virus produced by this method, and vector composition based on parts of recombinant influenza virus.

Inactivated vaccine against avian influenza emulsifified by flu protect h5 and method of avian influenza prevention / 2350350
Group of inventions concerns biotechnology. Vaccine includes antigen material of avian influenza virus, inactivant and adjuvant. A/Chicken/Novosibirsk/64/05 (H5N1) strain deposited in Russian State Virus Collection of State Institution D.I.Ivanovsky Virology Institute of Russian Medical Science Academy, certificate No 2373, is used as antigen material and reproduced in 9-13 day old chicken embryos and cell cultures in titres of 8.0-10.5 lg EID50/0.2 cm3, with hemagglutination activity of 5-10 log2. For avian influenza prevention bird stock undergoes vaccination by the claimed vaccine injected subcutaneously.

Method for vaccine injection / 2342156
Invention can be applied for subcutaneous fat post-injection injury preventing during subcutaneous injections of vaccine. To meet this object, the spot is anesthetised prior injection. Sodium chloride 0.9% solution is added to single dose of vaccine in proportion 1:5. Vaccine injection is implemented by manifold pricking around injection spot. Pricks are done at least 6 mm from each other, no more than 0.2 ml vaccine is injected at a time.